Comparative Pharmacology
Head-to-head clinical analysis: STIE CORT versus YUTIQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STIE CORT versus YUTIQ.
STIE-CORT vs YUTIQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; modulates gene expression leading to anti-inflammatory and immunosuppressive effects.
YUTIQ (fluocinolone acetonide intravitreal implant) is a corticosteroid that binds to glucocorticoid receptors, leading to inhibition of phospholipase A2, suppression of arachidonic acid release, and downregulation of pro-inflammatory mediators such as prostaglandins, leukotrienes, and cytokines. This reduces inflammation and vascular permeability in the eye.
Topical: Apply a thin film to affected area twice daily. Maximum 2-week continuous use. In severe cases, apply up to 4 times daily. Do not exceed 50 g/week.
0.18 mg fluocinolone acetonide intravitreal implant (single administration) releasing 0.2 mcg/day over 36 months.
None Documented
None Documented
Terminal elimination half-life is 1.5-2 hours (intravenous) and 2-3 hours (oral), reflecting rapid clearance; clinical context: supports twice-daily dosing for systemic effects.
Approximately 36 months (3 years) from the intravitreal implant; reflects sustained release from the non-biodegradable implant matrix.
Renal: 60-70% as metabolites; biliary/fecal: 20-30% as metabolites; unchanged drug: <5%.
Primarily hepatic/biliary; fecal excretion is the major route. Renal excretion of fluocinolone acetonide and metabolites accounts for <10%.
Category C
Category C
Corticosteroid
Corticosteroid